Then there were two: BeOne moves beyond single-blockbuster dependence
The company’s Sonrotoclax is the first newly approved BCL-2 inhibitor in the U.S. in nearly a decade, giving BeOne a potential new hit beyond its Zanubrutinib blood cancer therapy Key…
Recent Articles
Then there were two: BeOne moves beyond single-blockbuster dependence
6160.HK
688235.SHG
ONC.US
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- Mega licensing deal lifts 3SBio profits but core sales slip
- A healthy return: drug spin-off nets Keymed up to $320 million
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
